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O R I G I N A L A R T I C L E
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and on behalf of the EU-AIR Investigators
*Department of Endocrinology, Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds, UK, †Department of
Endocrinology, ‡Department of Medical and Health Sciences, Link€oping University, Link€oping, Sweden, §Shire, Lexington, MA,
USA, ¶Shire, Zug, Switzerland, **Endocrinology in Charlottenburg, Berlin, Germany and ††Department of Internal Medicine and
Endocrinology, University Medical Center Utrecht, Utrecht, The Netherlands
Summary
Context and objective Treatment for adrenal insufficiency
(AI) remains suboptimal. Despite glucocorticoid replacement,
patients with AI have reduced life expectancy and quality of life.
This study aimed to describe the spectrum of management of
glucocorticoid replacement in patients with AI enrolled in the
European Adrenal Insufficiency Registry (EU-AIR).
Design, setting and patients EU-AIR is a prospective, multi-
national, multicentre, observational study initiated in August
2012 to monitor the long-term safety of glucocorticoid replace-
ment in routine clinical practice in Germany, the Netherlands,
Sweden and the UK (ClinicalTrials.gov identifier: NCT01661387).
This analysis included 1166 patients with primary and secondary
AI (mean disease duration 161  116 years) receiving long-
term glucocorticoid replacement therapy.
Main outcome measure Glucocorticoid type, dose, frequency
and treatment regimen were examined.
Results Most patients (874%) were receiving hydrocortisone.
The most common dose range, taken by 422% of patients, was
20 to <25 mg/day; however, 126% were receiving doses of
≥30 mg/day. Hydrocortisone was being taken once daily by
55%, twice daily by 487%, three times daily by 436% and four
times daily by 21%. Patients with primary AI received higher
replacement doses than those with secondary AI (234  89
and 196  59 mg/day, respectively). Twenty-five different regi-
mens were being used to deliver a daily hydrocortisone dose of
20 mg.
Conclusions We have shown significant heterogeneity in the
type, dose, frequency and timing of glucocorticoid replacement
in real-world clinical practice. This reflects dose individualiza-
tion based on patient symptoms and lifestyle in the absence of
data supporting the optimal regimen.
(Received 12 August 2016; returned for revision 17 October 2016;
accepted 27 October 2016)
Introduction
Adrenal insufficiency (AI) is a life-threatening, rare disease
resulting from failure of glucocorticoid secretion in patients with
secondary AI and additionally mineralocorticoid secretion in the
less common case of primary AI (Addison’s disease). Left
untreated, acute adrenal failure can result in dehydration,
hypotension and hypovolemic shock, and can be fatal, particu-
larly during times of intercurrent illness.1 AI was first described
by Thomas Addison during his work at Guy’s Hospital, London
in 1855. Despite recognition of the condition, AI remained
invariably fatal until the 1930s owing to the lack of any disease-
specific treatment.2 It was at this time that the first clinical
evidence that extracts of animal adrenocortical tissue could
counteract the adverse sequelae of AI in humans became avail-
able. Cortisone was first successfully used as a steroid replace-
ment therapy in 1948.3 Six more synthetic glucocorticoids
became available for the treatment of AI during the mid-1950s.
With the development of steroid replacement, it was generally
assumed that individuals with Addison’s disease could expect to
have a relatively normal lifespan, provided that they manage
their daily medication appropriately, including taking intercur-
rent illnesses and stresses into consideration. Current glucocorti-
coid replacement therapy undoubtedly extends the life
expectancy of patients with AI; however, two large registry-based
studies in patients with Addison’s disease have shown that the
relative risk of death for these patients is more than double that
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of the background population, despite glucocorticoid replace-
ment.4–6 Furthermore, these individuals report impaired quality
of life, reduced perception of general health and an adverse
impact on physical activity, and family, social and work life (in-
cluding absenteeism from work).7,8
Current treatment of AI entails the use of one of the sev-
eral oral glucocorticoids, usually administered in multiple
small doses throughout the day, with the aim of mimicking
the normal diurnal cortisol secretion pattern. For patients
with primary AI, the addition of mineralocorticoid replace-
ment is also important. The lack of a suitable biomarker for
optimizing glucocorticoid replacement means that treatment is
guided by subjective health status and clinical assessment of
signs and symptoms of glucocorticoid over- and under-repla-
cement. There are a number of variables to consider when
using glucocorticoid replacement therapy, including the type
of glucocorticoid, total daily dose, number of individual doses
that the total daily dose is split into, and the timing of the
individual doses. We aimed to establish current patterns of
glucocorticoid usage within specialist endocrinology centres, by




EU-AIR is a prospective, multinational, multicentre, observa-
tional study sponsored by Shire. It was initiated in August 2012
to monitor the long-term safety of both modified-release hydro-
cortisone and conventional glucocorticoid replacement therapies
during routine clinical practice in patients with chronic AI
(ClinicalTrials.gov identifier: NCT01661387). The study focuses
on determining the frequency of intercurrent illnesses, adrenal
crises and serious adverse events. Data are currently being col-
lected from endocrinology centres in the UK, Germany, the
Netherlands and Sweden (Figure S1).
All patients with a diagnosis of AI [primary AI, secondary AI
or congenital adrenal hyperplasia (CAH)] who are receiving
long-term glucocorticoid replacement therapy are eligible for
inclusion in the study. All treatment decisions are made by the
registry physician and/or patient, and routine visits occur every
6–12 months. Patient diaries are used to record intercurrent ill-
nesses and illness-related dose changes between visits; this infor-
mation is entered into the database at subsequent clinic visits.
Comprehensive baseline data are collected at enrolment, as
described previously.9
Ethics
The study has been approved by the appropriate local
research ethics committees for all participating centres and is
being conducted in accordance with the Declaration of Hel-
sinki. Written informed consent/assent is provided by each
patient and/or their parent(s)/legal guardian(s) before enrol-
ment in EU-AIR.
Data collection and analysis
This descriptive analysis was performed on baseline data from
patients with primary or secondary AI receiving conventional
glucocorticoid replacement therapy, who were enrolled in the
EU-AIR between 8 August 2012 and 13 May 2015. As patients
with CAH frequently receive greater than physiological glucocor-
ticoid doses, these individuals were excluded from the current
analysis. Additionally, patients receiving modified-release hydro-
cortisone were excluded, as this subcohort predominantly com-
prised patients from the pivotal study of efficacy of this
formulation,10 and therefore were unlikely to be receiving treat-
ment representative of current clinical practice.
Patients were categorized according to the drug they were
receiving at baseline: hydrocortisone, prednisolone, cortisone
acetate or dexamethasone. The dose, frequency and times at
which patients were taking hydrocortisone and prednisolone
were examined. Patients taking other glucocorticoid replacement
therapies, and those taking more than one medication at base-
line, were counted in a category labelled ‘others’. Each patient
was represented only once within a particular drug category.
To ensure that the treatment at baseline was not related to
emergency/temporary use of medication, a 28-day period after
the date of enrolment was examined. Exposure records with a
duration of <28 days were excluded. Patients reporting multiple
dosing records for their therapy within 28 days after enrolment
were counted only at the highest dosage and the highest fre-
quency associated with that dosage.
Descriptive statistics were used to analyze data; these included
the number and percentage of observations, median, mean and
standard deviation (SD).
Results
In total, 1462 patients with AI who were receiving conventional
glucocorticoid replacement therapy were enrolled between initia-
tion of the study and the data-cut on 13 May 2015. Patients
with CAH (n = 71) and patients receiving modified-release
hydrocortisone (n = 202) were excluded from the current analy-
sis. A further 23 individuals who had received glucocorticoids
for <28 days were excluded to be certain all patients analyzed
had a definite diagnosis of chronic AI. The study cohort thus
consists of 1166 patients: 364 (312%) with primary AI; 801
(687%) with secondary AI; and 1 (01%) in whom AI aetiology
was not documented.
Patient demographics
The overall study cohort was of mean  SD age
543  160 years, 525% female, with an average disease dura-
tion of 161  116 years from diagnosis (Table 1). The mean
age was similar for patients with primary (520  158 years)
and secondary AI (552  160 years). Patients with primary AI
showed a slight female preponderance (651%), whereas those
with secondary AI showed a similar proportion of females
(467%) and males. Patients with primary AI had slightly longer
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd
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mean duration of disease than those with secondary AI
(176  128 years and 154  109 years, respectively).
Glucocorticoid replacement therapy
Hydrocortisone was the most frequently used glucocorticoid
replacement therapy, with 874% of all patients receiving this
steroid; 51% patients were receiving prednisolone; 40% corti-
sone acetate; and 01% were receiving dexamethasone. Data on
glucocorticoid use were missing for 27% of patients, and 07%
of patients were receiving other glucocorticoids or more than
one type of glucocorticoid concurrently. Hydrocortisone was the
most commonly utilized glucocorticoid replacement therapy in
patients with both primary (849%) and secondary AI (885%)
[difference: 36%; 95% confidence interval (CI) = 07% to
79%]. Of the patients not receiving hydrocortisone, a greater
proportion were from the Netherlands, and fewer from the UK,
when compared with those receiving hydrocortisone. The mean
hydrocortisone dose equivalent was also lower in those who
were not receiving hydrocortisone (141  119 mg vs
207  72 mg, respectively; Table S1).
Hydrocortisone-treated patients
In patients receiving hydrocortisone, the daily dose varied
widely, ranging from 5 mg to >45 mg. The most common dose
range taken by patients with AI was 20 to <25 mg/day (Fig. 1),
which was being taken by 422% of patients. Doses of 15 to
<20 mg/day were being taken by 229% of patients, and doses of
25 to <30 mg/day by 152% of patients. Therefore, 803% of
patients were receiving a daily hydrocortisone dose of 15 to
<30 mg. In total, 126% of patients were receiving hydrocorti-
sone doses of 30 mg/day or more. A greater proportion of
patients with primary AI were receiving hydrocortisone doses of
30 mg/day or more compared with those with secondary AI
[214% vs 88%, respectively (difference: 126%; 95% CI = 76–
176%)]. Patients with primary AI received higher mean daily
hydrocortisone doses compared with those with secondary AI
[234  89 and 196  59 mg/day, respectively (difference:
38 mg/day; 95% CI = 29–48 mg/day)]. Overall, doses of
hydrocortisone differed depending on the frequency of dosing
(Fig. 2): median of 10 mg for once daily (n = 56), 20 mg for
twice daily (n = 496), 20 mg for three times daily (n = 444) and
25 mg for four times daily regimens (n = 21).
Hydrocortisone was being taken once daily by 56 patients
(55%), twice daily by 496 patients (487%), three times daily by
444 patients (436%) and four times daily by 21 patients (21%).
Two patients (02%) were taking hydrocortisone at a higher fre-
quency. Patients with primary AI were more likely to be receiv-
ing hydrocortisone three times daily than those with secondary
AI [537% vs 392%, respectively (difference: 145%; 95%
CI = 79–211%); Fig. 3]. Conversely, patients with secondary AI
were more likely to be taking hydrocortisone twice daily than
those with primary AI [529% vs 388%, respectively (difference:
141%; 95% CI = 75–206%)].
The timing at which patients received their glucocorticoids
[morning (05:01–11:00 h), midday (11:01–15:00 h), afternoon
(15:01–18:00 h), evening (18:01–20:00 h), bedtime (21:01–
00:00 h) and overnight (00:01–05:00 h)] was recorded. Using
these data, we examined the variation in how a daily hydrocorti-
sone dose of 20 mg was delivered. Twenty-five different regi-
mens were being used to deliver a daily dose of 20 mg
hydrocortisone; the most common regimen (used by 282% of
patients) was 10 mg administered in the morning, 5 mg at mid-
day and 5 mg in the evening (Fig. 4). The second most frequent
regimen was use of hydrocortisone as a twice-daily regime:
10 mg in the morning and a further 10 mg at midday (180%).
The third most common regimen was 10 mg administered in
the morning, 5 mg at midday and 5 mg in the afternoon
(172%), differing only from the most common regimen by tak-
ing the last hydrocortisone dose earlier. These three most com-
mon regimens account for 633% of the regimens used to
deliver 20 mg hydrocortisone within this cohort.
Discussion
In this study, we observed considerable heterogeneity in the cur-
rent management of AI in terms of dosage, frequency of admin-
istration, dose regimen and type of glucocorticoid used.
Notably, the majority of patients with primary and secondary AI
were treated with hydrocortisone, with a daily dosage of 15 to
<30 mg, and administered using a twice- or thrice-daily regi-
men. Greater divergence was observed, however, in the regimen
by which the glucocorticoid was administered, as exemplified by
Table 1. Demographic parameters of patients enrolled into the EU-AIR
Primary AI Secondary AI Overall
Patient number, n 364 801 1166
Female, n (%) 237 (651) 374 (467) 612 (525)
Age, years, mean  SD 520  158 552  160 543  160
Disease duration, years, n (mean  SD) 364 (176  128) 800 (154  109) 1164 (161  116)
BMI, kg/m2, n (mean  SD) 321 (262  48) 695 (288  51) 1016 (270  52)
Diabetes, n (%) 51 (140) 94 (117) 145 (124)
Hypertension, n (%) 92 (253) 263 (328) 355 (304)
AI, adrenal insufficiency; BMI, body mass index; EU-AIR, European Adrenal Insufficiency Registry; SD, standard deviation.
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd
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our examination of patients receiving a daily hydrocortisone of
20 mg. Within this latter group, we identified 25 different regi-
mens with which the therapy was administered. Although the
daily doses of hydrocortisone used by clinicians in real-world
practice varied widely from doses considered subtherapeutic
(5 mg) to supra-physiological (>45 mg), the majority of patients
received a daily dosage within the range of 15 to <30 mg.
The prevalence of primary AI in Western Europe is estimated
to be 93–140 per million,11,12 and that of secondary AI to be
290–455 per million population.13 Due to the low prevalence of
AI, adequately powered controlled studies of glucocorticoid regi-
mens, whether comparing different glucocorticoid types or
doses, are difficult to perform. Placebo-controlled studies are
plagued with difficulty because of potential confusion over the
management of increases in glucocorticoids during periods of
intercurrent illness. It is unlikely that adequately powered
prospective studies based upon the hard end-points of mortality,
fracture rates and rates of adrenal crisis will be performed.
Therefore, what few studies there are depend on the surrogate
measurement of bone density, body composition, metabolism,
surrogates of vascular risk, and quality of life. Therefore, data
relating to optimal glucocorticoid replacement regimens to date
have been derived from open and observational studies includ-
ing small numbers of patients.14–17 In contrast, the EU-AIR is a
large, multinational registry for patients with AI, which is
prospectively collecting observational data on the current man-
agement of AI, metabolic parameters and patient outcomes.9
Analysis of these data will, over time, provide powerful evidence
on which to base controlled studies, with the aim of determining
best practice for the management of AI. The present analysis
imparts considerable knowledge on how AI is currently man-
aged, and the significant variability in the approaches taken.
The intention of current treatment regimens is to mimic the
normal circadian pattern of endogenous plasma cortisol. How-
ever, in the absence of a specific biomarker to guide glucocorti-




































































Daily hydrocortisone dose (mg)
Fig. 1 Proportion of patients enrolled into the EU-
AIR receiving different doses of hydrocortisone at



































Fig. 2 Mean hydrocortisone doses according to the frequency of
administration. Solid line – primary adrenal insufficiency: Dashed line –
secondary adrenal insufficiency. Data are presented as mean  standard





























Hydrocortisone dose frequency 
Primary AI
Secondary AI
Fig. 3 Proportion of patients enrolled in the EU-
AIR receiving different hydrocortisone dose
frequencies at baseline. AI, adrenal insufficiency;
BID, twice daily; QD, once daily; QID, four times
daily; TID, three times daily.
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd
Clinical Endocrinology (2017), 86, 340–346
Heterogeneity in the management of AI 343
status of the individual, alongside clinical assessment of signs
and symptoms of glucocorticoid over- or under-replacement.
These variables lead to individualization of glucocorticoid
replacement regimens. This analysis highlights that a multitude
of different regimens, in terms of dosage, frequency, dose regi-
men and glucocorticoid type, are utilized.
From stable isotope dilution and deconvolution analyses, cor-
tisol production rates are estimated to be 57–74 mg/m2 per
day, which translates to an equivalent daily hydrocortisone dose
of 15–20 mg for cortisol replacement.18–20 In this study, the
majority of patients (80%) were taking daily doses of 15 to
<30 mg. This would be in keeping with the recent Endocrine
Society Clinical Practice Guideline for the diagnosis and treat-
ment of primary AI, which recommends a daily hydrocortisone
dose of 15–25 mg.21 Notably, however, around one in eight
(126%) patients was receiving hydrocortisone doses of 30 mg/
day or more. A substantial proportion of patients within our
cohort therefore appear to be over-replaced, increasing the risk
of reduced bone mineral density, cardiovascular disease and an
adverse metabolic profile.1,14,18,22,23
The cardiometabolic profile of the patients in this analysis
suggests the possibility of glucocorticoid over replacement, in
that mean body mass index (BMI) was elevated, and a substan-
tial proportion had diabetes or hypertension. However, in the
absence of a matched control group, it is difficult to make firm
conclusions in this regard. In hypopituitary patients, both BMI
and serum cholesterol levels are positively correlated with gluco-
corticoid doses.22 Furthermore, glucocorticoid over replacement
may impact on quality of life; patients taking hydrocortisone
doses of 30 mg/day or more experience greater impairment of
health-related quality of life compared with those taking lower
doses.24
At the other end of the spectrum, inadequate glucocorticoid
replacement also has important clinical consequences. In this
study, 72% of patients were receiving hydrocortisone doses of
<15 mg/day. This dosage may be sufficient in some patients with
secondary AI with partial adrenocorticotropic hormone defi-
ciency. While metabolic end-points in patients receiving daily
hydrocortisone equivalent doses of <20 mg do not differ from
patients who are glucocorticoid replete,22 under-replacement has
been associated with symptoms of fatigue, nausea, myalgia and
joint stiffness, and an increased risk of adrenal crisis. In a study
of 53 patients with AI, adrenal crises were most frequently due
to glucocorticoid dose reduction or a lack of stress-related dose
adjustment.1
In addition to the total amount of cortisol produced daily, it
is intuitive to expect that the diurnal variation in cortisol levels
is important. The frequency and regimen with which patients
20·0 mg in morning (n = 4)
10·0 mg in morning; 10·0 mg at midday (n = 74)
10·0 mg in morning; 10·0 mg in afternoon (n = 25)
10·0 mg in morning; 10·0 mg in evening (n = 14)
12·5 mg in morning; 7·5 mg in afternoon (n = 2)
15·0 mg in morning; 5·0 mg at midday (n = 35)
15·0 mg in morning; 5·0 mg in afternoon (n = 25)
15·0 mg in morning; 5·0 mg in evening (n = 12)
10·0 mg in morning; 5·0 mg at midday; 5·0 mg in afternoon (n = 71)
10·0 mg in morning; 5·0 mg at midday; 5·0 mg in evening (n = 116)
10·0 mg in morning; 7·5 mg at midday; 2·5 mg in afternoon (n = 2)
12·5 mg in morning; 5·0 mg at midday; 2·5 mg in afternoon (n = 5)
10·0 mg in morning; 5·0 mg at midday; 2·5 mg in afternoon; 
2·5 mg in evening (n = 1)
10·0 mg in morning; 5·0 mg in afternoon; 5·0 mg at bedtime (n = 5)






Fig. 4 Dosing regimens used to administer a total daily dose of 20 mg of hydrocortisone. BID, twice daily; HC, hydrocortisone; QD, once daily; QID,
four times daily; TID, three times daily. aData were available for 412 patients in total. bTwo further QD, three further BID regimens and five further
TID regimens were used by one patient each.
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take glucocorticoid replacement may therefore also be of clinical
significance.25 The majority of patients within our study who
were receiving hydrocortisone were receiving this treatment
twice or three times daily. Similar to the previously commented-
upon recommended hydrocortisone dose, our observation on
dosing frequency is in keeping with the recent recommendations
within the Endocrine Society Clinical Practice Guideline for the
diagnosis and treatment of primary AI, which recommends that
the daily dose is applied in two to three doses.21 Nevertheless,
there was considerable heterogeneity in the frequency of admin-
istration and the regimen used to administer the divided doses.
As an example, we described 25 different regimens used to deli-
ver a daily hydrocortisone dose of 20 mg. The majority of these
regimens provide a larger dose on waking, followed by one or
two smaller doses throughout the day to approximate the physi-
ological cortisol secretion profile.26 How glucocorticoid replace-
ment is delivered is of importance, as it can result in
nonphysiological spikes and troughs in cortisol levels and night-
time cortisol exposure. The well-being of patients with AI is
improved by closer mimicking of the normal cortisol secretion
pattern, by either administering hydrocortisone more frequently
or using continuous subcutaneous hydrocortisone infusions.27–29
A recent study showed that patients prefer four times daily dos-
ing to twice daily dosing when comparing equivalent overall
doses of hydrocortisone.27 Patients on four times daily dosing
reported less fatigue, feeling more alert during the day and a less
varied treatment effect. A caveat to interpreting these data, how-
ever, is that for a given dose of hydrocortisone, the relative
bioavailability increases with the frequency of dosing.27,30
It has been shown that glucocorticoid replacement regimens
that result in exposure to exogenous glucocorticoids late in the
day, when physiological levels would normally be low, worsen
carbohydrate handling compared with regimens where the
dosage is delivered earlier.25 The cortisol exposure profile,
determined by the frequency and timing of glucocorticoid
doses, may therefore be important in determining patient out-
comes, in addition to the total daily dose. Further data are,
however, needed to fully understand the impact of glucocorti-
coid replacement regimens on metabolism and long-term
patient outcomes.
It is noteworthy that patients with primary AI were receiving
higher mean daily doses of hydrocortisone than those with sec-
ondary AI. This may reflect the fact that patients with secondary
AI frequently retain some residual cortisol secretion, whereas
this is much less frequent in patients with primary AI.1 On a
similar note, patients with primary AI most frequently received
hydrocortisone three times daily, in contrast to patients with
secondary AI, who most frequently received twice daily doses.
The assumption here is also that patients with secondary AI
have sufficient residual cortisol secretion between doses to allow
less frequent dosing without adverse effects on subjective well-
being. In addition, it might be the case that in primary AI, too
low fludrocortisone doses are used and are compensated by
higher hydrocortisone doses.31
In addition to the uncontrolled nature of databases such as
EU-AIR, it must be recognized that the centres participating in
this study could all be considered as providers of tertiary care to
patients with AI. It is therefore not possible to fully generalize
the findings to those of less specialist centres where doses of glu-
cocorticoids and their delivery may differ significantly from
those described here.
In summary, we have shown significant heterogeneity in the
type, dose, frequency and timing of glucocorticoid replacement
therapy used in real-world clinical practice. This likely reflects
dose individualization based on patient symptoms and lifestyle.
We have additionally highlighted that many patients are
receiving supra-physiological glucocorticoid doses that may, at
least in part, be responsible for the adverse cardiometabolic
profile of these individuals. The EU-AIR has the potential to
provide data from large numbers of patients with AI, which
will help determine ‘best practice’ in the management of these
patients.
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